MedKoo product information:

Alanosine

Description of L-alanosine: L-alanosine is an amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities. L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency. The clinical use of this agent may be limited by its toxicity profile. MTAP is a key enzyme in the adenine and methionine salvage pathways. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer:    Gilead (Originator)

 1: Efferth T. Personalized Cancer Medicine: From Molecular Diagnostics to Targeted Therapy with Natural Products. Planta Med. 2010 May 19. [Epub ahead of print] PubMed PMID: 20486071.

2: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):463-93. PubMed PMID: 19907722.

3: Kindler HL, Burris HA 3rd, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs. 2009 Feb;27(1):75-81. Epub 2008 Jul 11. PubMed PMID: 18618081.

4: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735. PubMed PMID: 18200333.

5: Bonomo J, Lynch MD, Warnecke T, Price JV, Gill RT. Genome-scale analysis of anti-metabolite directed strain engineering. Metab Eng. 2008 Mar;10(2):109-20. Epub 2007 Nov 5. PubMed PMID: 18093856.

6: Bilodeau-Goeseels S, Sasseville M, Guillemette C, Richard FJ. Effects of adenosine monophosphate-activated kinase activators on bovine oocyte nuclear maturation in vitro. Mol Reprod Dev. 2007 Aug;74(8):1021-34. PubMed PMID: 17290417.

7: Marcé S, Balagué O, Colomo L, Martinez A, Höller S, Villamor N, Bosch F, Ott G, Rosenwald A, Leoni L, Esteller M, Fraga MF, Montserrat E, Colomer D, Campo E. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res. 2006 Jun 15;12(12):3754-61. PubMed PMID: 16778103.

8: Li XM, Kanekal S, Crépin D, Guettier C, Carrière J, Elliott G, Lévi F. Circadian pharmacology of L-alanosine (SDX-102) in mice. Mol Cancer Ther. 2006 Feb;5(2):337-46. PubMed PMID: 16505107.

9: Huang J, Lipscomb WN. T-state active site of aspartate transcarbamylase: crystal structure of the carbamyl phosphate and L-alanosine ligated enzyme. Biochemistry. 2006 Jan 17;45(2):346-52. PubMed PMID: 16401065.

10: Karikari CA, Mullendore M, Eshleman JR, Argani P, Leoni LM, Chattopadhyay S, Hidalgo M, Maitra A. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Mol Cancer Ther. 2005 Dec;4(12):1860-6. PubMed PMID: 16373701.

11: Batova A, Cottam H, Yu J, Diccianni MB, Carrera CJ, Yu AL. EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood. 2006 Feb 1;107(3):898-903. Epub 2005 Oct 18. PubMed PMID: 16234352; PubMed Central PMCID: PMC1895892.

12: Powell EL, Leoni LM, Canto MI, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, Maitra A, Montgomery E. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol. 2005 Nov;29(11):1497-504. PubMed PMID: 16224217.

13: Huang Y, Dai Z, Barbacioru C, Sadée W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005 Aug 15;65(16):7446-54. PubMed PMID: 16103098.

14: Capella G, Caldas C. MTAP homozygous deletion: an Achilles heel of human cancers ready for clinical use? Cancer Biol Ther. 2005 Mar;4(3):347. Epub 2005 Mar 9. PubMed PMID: 15876862.

15: Li W, Su D, Mizobuchi H, Martin DS, Gu B, Gorlick R, Cole P, Bertino JR. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncol Res. 2004;14(7-8):373-9. PubMed PMID: 15301428.

16: Gantverg A, Elliott G, Pineault J, Demers R. Determination of derivatized l-alanosine in plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):311-5. PubMed PMID: 15063341.

17: Efferth T, Gebhart E, Ross DD, Sauerbrey A. Identification of gene expression profiles predicting tumor cell response to L-alanosine. Biochem Pharmacol. 2003 Aug 15;66(4):613-21. PubMed PMID: 12906926.

18: Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003 Jun;9(6):2108-13. PubMed PMID: 12796375.

19: Harasawa H, Yamada Y, Kudoh M, Sugahara K, Soda H, Hirakata Y, Sasaki H, Ikeda S, Matsuo T, Tomonaga M, Nobori T, Kamihira S. Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). Leukemia. 2002 Sep;16(9):1799-807. PubMed PMID: 12200696.

20: Efferth T, Miyachi H, Drexler HG, Gebhart E. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. Blood Cells Mol Dis. 2002 Jan-Feb;28(1):47-56. PubMed PMID: 11987241.

21: Yu J. Alanosine (UCSD). Curr Opin Investig Drugs. 2001 Nov;2(11):1623-30. Review. PubMed PMID: 11763167.

22: Dagher PC. Modeling ischemia in vitro: selective depletion of adenine and guanine nucleotide pools. Am J Physiol Cell Physiol. 2000 Oct;279(4):C1270-7. PubMed PMID: 11003607.

23: Batova A, Diccianni MB, Omura-Minamisawa M, Yu J, Carrera CJ, Bridgeman LJ, Kung FH, Pullen J, Amylon MD, Yu AL. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Res. 1999 Apr 1;59(7):1492-7. PubMed PMID: 10197619.

24: Yu J, Batova A, Shao L, Carrera CJ, Yu AL. Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies. Clin Cancer Res. 1997 Mar;3(3):433-8. PubMed PMID: 9815702.

25: Downs SM. Involvement of purine nucleotide synthetic pathways in gonadotropin-induced meiotic maturation in mouse cumulus cell-enclosed oocytes. Mol Reprod Dev. 1997 Feb;46(2):155-67. PubMed PMID: 9021747.

26: Hori H, Tran P, Carrera CJ, Hori Y, Rosenbach MD, Carson DA, Nobori T. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res. 1996 Dec 15;56(24):5653-8. PubMed PMID: 8971171.

27: Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L, Yu AL. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood. 1996 Oct 15;88(8):3083-90. PubMed PMID: 8874207.

28: Finch RA, Chan PK. ATP depletion affects NPM translocation and exportation of rRNA from nuclei. Biochem Biophys Res Commun. 1996 May 15;222(2):553-8. PubMed PMID: 8670243.

29: Palos TP, Ramachandran B, Boado R, Howard BD. Rat C6 and human astrocytic tumor cells express a neuronal type of glutamate transporter. Brain Res Mol Brain Res. 1996 Apr;37(1-2):297-303. PubMed PMID: 8738164.

30: Brosh S, Zoref-Shani E, Danziger E, Bromberg Y, Sperling O, Sidi Y. Adenine nucleotide metabolism in primary rat neuronal cultures. Int J Biochem Cell Biol. 1996 Mar;28(3):319-28. PubMed PMID: 8920641.

31: Musk P, Clark JM, Thompson D, Dunn IS, Christopherson RI, Szabados E, Rose SE, Parsons PG. Purine deoxynucleoside metabolism in human melanoma cells with a high spontaneous mutation rate. Mutat Res. 1996 Feb 19;350(1):229-38. PubMed PMID: 8657185.

32: Meredith M, Rabaglia M, Metz S. Cytosolic biosynthesis of GTP and ATP in normal rat pancreatic islets. Biochim Biophys Acta. 1995 Apr 6;1266(1):16-22. PubMed PMID: 7718617.

33: Ahmed N, Weidemann MJ. Biochemical effect of three different inhibitors of purine/pyrimidine metabolism on differentiation in HL60 cells. Leuk Res. 1995 Apr;19(4):263-73. PubMed PMID: 7538618.

34: Datta SK, Guicherit OM, Kellems RE. Adenylosuccinate synthetase: a dominant amplifiable genetic marker in mammalian cells. Somat Cell Mol Genet. 1994 Sep;20(5):381-9. PubMed PMID: 7825060.

35: Downs SM. High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants. Biol Reprod. 1994 Jun;50(6):1403-12. PubMed PMID: 8080928.

36: Guicherit OM, Cooper BF, Rudolph FB, Kellems RE. Amplification of an adenylosuccinate synthetase gene in alanosine-resistant murine T-lymphoma cells. Molecular cloning of a cDNA encoding the "non-muscle" isozyme. J Biol Chem. 1994 Feb 11;269(6):4488-96. PubMed PMID: 8308018.

37: Ramachandran B, Houben K, Rozenberg YY, Haigh JR, Varpetian A, Howard BD. Differential expression of transporters for norepinephrine and glutamate in wild type, variant, and WNT1-expressing PC12 cells. J Biol Chem. 1993 Nov 15;268(32):23891-7. PubMed PMID: 8226929.

38: Alenin VV, Ostanin KV, Kostikova TR, Domkin VD, Zubova VA, Smirnov MN. [Substrate specificity of phosphoribosyl-aminoimidazole-succinocarboxamide synthetase (SAICAR-synthetase) from Saccharomyces cerevisiae yeast]. Biokhimiia. 1992 Jun;57(6):845-55. Russian. PubMed PMID: 1420588.

39: Von Hoff DD, Green SJ, Neidhart JA, Fabian C, Budd T, Boyd JF, Osborne CK. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1991 Feb;9(1):87-8. PubMed PMID: 2026487.

40: Peeters MA, Rethoré MO, Aris L, Megarbane A, Cattaneo F, Lejeune J. Metabolic anomalies in cri du chat syndrome (5p-) lymphocytes and de novo purine synthesis. Ann Genet. 1991;34(3-4):219-25. PubMed PMID: 1809230.

41: Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther. 1990;46(2):243-71. Review. PubMed PMID: 2108451.

42: Hong SS, Alfieri AA, Kim SH, Kim JH. Increased tumor control rates in murine fibrosarcoma by combined therapy with L-alanosine and radiation. Jpn J Cancer Res. 1989 Jun;80(6):592-6. PubMed PMID: 2503478.

43: Pang JC, Du RP, Bingham H, Juranka P, Chan VL. Imbalance of purine nucleotides in alanosine-resistant baby hamster kidney cells. Somat Cell Mol Genet. 1989 Mar;15(2):101-11. PubMed PMID: 2538926.

44: Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG, Fridland A. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem. 1988 Oct 25;263(30):15354-7. PubMed PMID: 3262616.

45: Elson PJ, Kvols LK, Vogl SE, Glover DJ, Hahn RG, Trump DL, Carbone PP, Earle JD, Davis TE. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs. 1988 Jun;6(2):97-103. PubMed PMID: 3170135.

46: Bennett LL Jr, Brockman RW, Allan PW, Rose LM, Shaddix SC. Alterations in nucleotide pools induced by 3-deazaadenosine and related compounds. Role of adenylate deaminase. Biochem Pharmacol. 1988 Apr 1;37(7):1233-44. PubMed PMID: 3355597.

47: Daniels R, Gerbracht T, Flickinger RA. Cell growth and division in relation to differentiation of mouse erythroleukemia cells. Cell Biol Int Rep. 1988 Apr;12(4):299-303. PubMed PMID: 3165307.

48: Miller FR, McInerney D, Rogers C, Miller BE. Spontaneous fusion between metastatic mammary tumor subpopulations. J Cell Biochem. 1988 Feb;36(2):129-36. PubMed PMID: 3356752.

49: Ahluwalia G, Cooney DA, Mitsuya H, Fridland A, Flora KP, Hao Z, Dalal M, Broder S, Johns DG. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797-800. PubMed PMID: 3120727.

50: Morton RF, Creagan ET, Cullinan SA, Mailliard JA, Ebbert L, Veeder MH, Chang M. Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. J Clin Oncol. 1987 Jul;5(7):1078-82. PubMed PMID: 3598611.

51: Casey PJ, Lowenstein JM. Inhibition of adenylosuccinate lyase by L-alanosyl-5-aminoimidazole-4-carboxylic acid ribonucleotide (alanosyl-AICOR). Biochem Pharmacol. 1987 Mar 1;36(5):705-9. PubMed PMID: 3827951.

52: Downs SM, Eppig JJ. Induction of mouse oocyte maturation in vivo by perturbants of purine metabolism. Biol Reprod. 1987 Mar;36(2):431-7. PubMed PMID: 2883997.

53: Baillon J, Tauc P, Hervé G. L-alanosine: a noncooperative substrate for Escherichia coli aspartate transcarbamylase. Biochemistry. 1985 Dec 3;24(25):7182-7. PubMed PMID: 3910096.

54: Turker MS, Martin GM. Induction of adenine salvage in mouse cell lines deficient in adenine phosphoribosyltransferase. Mol Cell Biol. 1985 Oct;5(10):2662-8. PubMed PMID: 3837181; PubMed Central PMCID: PMC367003.

55: Alston TA, Porter DJ, Bright HJ. Generation of nitric oxide by enzymatic oxidation of N-hydroxy-N-nitrosamines. J Biol Chem. 1985 Apr 10;260(7):4069-74. PubMed PMID: 3980468.

56: Galliani G, Assandri A, Barone D, Grandi M, Mistrello G, Lancini GC. Contragestational profile of the tumor-inhibiting agent, L-alanosine, in the rat and the hamster. Cancer Chemother Pharmacol. 1985;14(1):74-8. PubMed PMID: 3965163.

57: Strazzolini P, Malabarba A, Ferrari P, Grandi M, Cavalleri B. Synthesis and in vitro biological evaluation of N-[(5-amino-1-beta-D-ribofuranosyl-1H-imidazol-4-yl)carbonyl]-3- (hydroxynitrosamino)-L-alanine (L-alanosine AICO ribonucleoside). J Med Chem. 1984 Oct;27(10):1295-9. PubMed PMID: 6592359.

58: Creagan ET, Long HJ, Ahmann DL, Green SJ. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. Am J Clin Oncol. 1984 Oct;7(5):543-4. PubMed PMID: 6507375.

59: Chitnis MP, Adwankar MK, Amonkar AJ. Antitumor effect of L-alanosine (NSC 153553) on sensitive and resistant sublines of murine leukemias. Tumori. 1984 Aug 31;70(4):317-20. PubMed PMID: 6474581.

60: Nguyen BT, El Sayed YM, Sadée W. Interaction among the distinct effects of adenine and guanine depletion in mouse lymphoma cells. Cancer Res. 1984 Jun;44(6):2272-7. PubMed PMID: 6722768.

61: Webster HK, Whaun JM, Walker MD, Bean TL. Synthesis of adenosine nucleotides from hypoxanthine by human malaria parasites (Plasmodium falciparum) in continuous erythrocyte culture: inhibition by hadacidin but not alanosine. Biochem Pharmacol. 1984 May 1;33(9):1555-7. PubMed PMID: 6375681.

62: Wang CC, Verham R, Cheng HW, Rice A, Wang AL. Differential effects of inhibitors of purine metabolism on two trichomonad species. Biochem Pharmacol. 1984 Apr 15;33(8):1323-9. PubMed PMID: 6608946.

63: Lieber MM. Soft agar colony formation assay for in vitro chemotherapy sensitivity testing of human renal cell carcinoma: Mayo Clinic experience. J Urol. 1984 Feb;131(2):391-3. PubMed PMID: 6199522.

64: Mistrello G, Bassi L. Effect of L-alanosine on immune response. J Immunopharmacol. 1984;6(1-2):25-41. PubMed PMID: 6470495.

65: Tyagi AK, Cooney DA. Biochemical pharmacology, metabolism, and mechanism of action of L-alanosine, a novel, natural antitumor agent. Adv Pharmacol Chemother. 1984;20:69-121. Review. PubMed PMID: 6398969.

66: O'Connell MJ, Rubin J, Schutt AJ, Moertel CG, Kvols LK. Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma. Cancer Treat Rep. 1983 Dec;67(12):1141-2. PubMed PMID: 6360350.

67: Creagan ET, Schutt AJ, Ingle JN, O'Fallon JR. Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer. Cancer Treat Rep. 1983 Nov;67(11):1047. PubMed PMID: 6640554.

68: Creagan ET, O'Connell MJ, Kovach JS. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer. Cancer. 1983 Aug 15;52(4):615-8. PubMed PMID: 6861099.

69: Yeung CY, Ingolia DE, Bobonis C, Dunbar BS, Riser ME, Siciliano MJ, Kellems RE. Selective overproduction of adenosine deaminase in cultured mouse cells. J Biol Chem. 1983 Jul 10;258(13):8338-45. PubMed PMID: 6602803.

70: Rubin J, Hineman V, Moertel CG, Schutt AJ, Hahn RG. A phase II study of alanosine in advanced large bowel carcinoma. Am J Clin Oncol. 1983 Apr;6(2):191-3. PubMed PMID: 6829493.

71: Goldsmith MA, Ohnuma T, Spigelman M, Greenspan EM, Holland JF. Phase I study of L-alanosine (NSC 15353). Cancer. 1983 Feb 1;51(3):378-80. PubMed PMID: 6821823.

72: Heimer R, Goldberg D, Cadman E. Modulation of fluoropyrimidine metabolism in L1210 cells by L-alanosine. Biochem Pharmacol. 1983 Jan 15;32(2):199-206. PubMed PMID: 6870949.

73: Weick JK, Tranum BL, Morrison FS. The treatment of acute leukemia with continuous infusion L-Alanosine. Invest New Drugs. 1983;1(3):249-51. PubMed PMID: 6678874.

74: Allsop J, Watts RW. Purine de novo synthesis in liver and developing rat brain, and the effect of some inhibitors of purine nucleotide interconversion. Enzyme. 1983;30(3):172-80. PubMed PMID: 6628351.

75: Powis G. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab Rev. 1983;14(6):1145-63. Review. PubMed PMID: 6373208.

76: Watts RW. Some regulatory and integrative aspects of purine nucleotide biosynthesis and its control: an overview. Adv Enzyme Regul. 1983;21:33-51. Review. PubMed PMID: 6152730.

77: Alston TA, Bright HJ. Enzymatic release of nitric oxide from L-alanosine, an antineoplastic antibiotic. Biochem Biophys Res Commun. 1982 Mar 30;105(2):560-6. PubMed PMID: 7092872.

78: Dosik GM, Stewart D, Valdivieso M, Burgess MA, Bodey GP. Phase I study of L-alanosine using a daily x 3 schedule. Cancer Treat Rep. 1982 Jan;66(1):73-6. PubMed PMID: 7053269.

79: Kang CY, Weide LG, Tischfield JA. Suppression of vesicular stomatitis virus defective intefering particle generation by a function(s) associated with human chromosome 16. J Virol. 1981 Dec;40(3):946-52. PubMed PMID: 6275129; PubMed Central PMCID: PMC256708.

80: Koch MR, Lea MA. Uptake of 14C-labeled dicarboxylic amino acids in hepatocytes and hepatoma cells. Cancer Res. 1981 Aug;41(8):3065-70. PubMed PMID: 7248963.

81: Tyagi AK, Cooney DA, Jayaram HN, Swiniarski JK, Johnson RK. Studies on the mechanism of resistance of selected murine tumors to L-alanosine. Biochem Pharmacol. 1981 May 1;30(9):915-24. PubMed PMID: 7236312.

82: Powis G, Kovach JS. Binding of copper and zinc by the antitumour agent L-alanosine. Biochem Pharmacol. 1981 Apr 1;30(7):771-6. PubMed PMID: 7247961.

83: Tyagi AK, Thake DC, McGee E, Cooney DA. Determinants of the toxicity of L-alanosine to various organs of the mouse. Toxicology. 1981;21(1):59-69. PubMed PMID: 7281196.

84: Tyagi AK, Cooney DA. Identification of the antimetabolite of L-alanosine, L-alanosyl-5-amino-4-imidazolecarboxylic acid ribonucleotide, in tumors and assessment of its inhibition of adenylosuccinate synthetase. Cancer Res. 1980 Dec;40(12):4390-7. PubMed PMID: 7438071.

85: Gupta RS. A novel synergistic effect of alanosine and guanine on adenine nucleotide synthesis in mammalian cells. Alanosine as a useful probe for investigating purine nucleotide metabolism. J Cell Physiol. 1980 Aug;104(2):241-8. PubMed PMID: 7410492.

86: Anandaraj SJ, Jayaram HN, Cooney DA, Tyagi AK, Han N, Thomas JH, Chitnis M, Montgomery JA. Interaction of L-alanosine (NSC 153, 353) with enzymes metabolizing L-aspartic acid, L-glutamic acid and their amides. Biochem Pharmacol. 1980 Feb;29(2):227-45. PubMed PMID: 7362636.

87: Jayaram HN, Tyagi AK, Anandaraj S, Montgomery JA, Kelley JA, Kelley J, Adamson RH, Cooney DA. Metabolites of alanosine, an antitumor antibiotic. Biochem Pharmacol. 1979 Dec 15;28(24):3551-66. PubMed PMID: 533558.

88: Jayaram HN, Cooney DA. Analogs of L-aspartic acid in chemotherapy for cancer. Cancer Treat Rep. 1979 Jun;63(6):1095-108. PubMed PMID: 38003.

89: Powis G, Ames MM. Determination of L-alanosine in plasma and urine by reversed-phase high-performance liquid chromatography of the Dns derivative. J Chromatogr. 1979 Feb 11;170(1):195-201. PubMed PMID: 544618.

90: Willis RC, Seegmiller JE. Increases in purine excretion and rate of synthesis by drugs inhibiting IMP dehydrogenase or adenylosuccinate synthetase activities. Adv Exp Med Biol. 1979;122B:237-41. PubMed PMID: 44644.

91: Dye FJ, Kollar EJ. Inhibition of mouse molar tooth germ morphogenesis in organ culture by alanosine. Exp Cell Biol. 1978;46(3):170-8. PubMed PMID: 627296.

92: Chan TS, Creagan RP, Reardon MP. Adenosine kinase as a new selective marker in somatic cell genetics: isolation of adenosine kinase--deficient mouse cell lines and human--mouse hybrid cell lines containing adenosine kinase. Somatic Cell Genet. 1978 Jan;4(1):1-12. PubMed PMID: 204068.

93: Kelley JM, Adamson RH, Cooney DA, Jayaram HN, Anandaraj S. Pharmacologic disposition of DL-alanosine in mice, rats, dogs, and monkeys. Cancer Treat Rep. 1977 Nov;61(8):1471-84. PubMed PMID: 411570.

94: Graff JC, Plagemann PG. Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate. Cancer Res. 1976 Apr;36(4):1428-40. PubMed PMID: 177207.

95: Kratsas RG. Decrease in fertility, fecundity, and egg size after feeding alanosine to Phormia regina. J Econ Entomol. 1975 Oct;68(5):581-2. PubMed PMID: 1184818.

96: Tischfield JA, Ruddle FH. Assignment of the gene for adenine phosphoribosyltransferase to human chromosome 16 by mouse-human somatic cell hybridization. Proc Natl Acad Sci U S A. 1974 Jan;71(1):45-9. PubMed PMID: 4129802; PubMed Central PMCID: PMC387928.

97: Pittillo RF, Woolley C. Microbiological assay for estimating concentrations of DL-alanosine in mouse tissue. Antimicrob Agents Chemother. 1973 Jun;3(6):739-41. PubMed PMID: 4597740; PubMed Central PMCID: PMC444490.

98: Eaton CN, Denny GH Jr, Ryder MA, Ly MG, Babson RD. Improved synthesis of DL-alanosine. J Med Chem. 1973 Mar;16(3):289-90. PubMed PMID: 4733112.

99: Kusano T, Long C, Green H. A new reduced human-mouse somatic cell hybrid containing the human gene for adenine phosphoribosyltransferase. Proc Natl Acad Sci U S A. 1971 Jan;68(1):82-6. PubMed PMID: 5276304; PubMed Central PMCID: PMC391107.

100: Fumarola D. Further investigations on the immunosuppressive effect of alanosine. Pharmacology. 1970;3(4):215-9. PubMed PMID: 5462270.

101: Fumarola D. Preliminary studies on the immunosuppressive action of alanosine. Pharmacology. 1970;3(2):107-12. PubMed PMID: 5445906.

102: Lancini GC, Lazzari E, Diena A. Synthesis of homologues of the antibiotic alanosine. Farmaco Sci. 1969 Feb;24(2):169-78. PubMed PMID: 5768828.

103: Gale GR, Atkins LM. Inhibition of glutamic acid carboxy-lyase by alanosine. Proc Soc Exp Biol Med. 1968 Dec;129(3):842-5. PubMed PMID: 5725103.

104: Gale GR, Smith AB. Alanosine and hadacidin--comparison of effects on adenylosuccinate synthetase. Biochem Pharmacol. 1968 Dec;17(12):2495-8. PubMed PMID: 4888630.

105: Gale GR, Ostrander WE, Atkins LM. Effects of alanosine on purine and pyrimidine synthesis. Biochem Pharmacol. 1968 Sep;17(9):1823-32. PubMed PMID: 5688270.

106: Gale GR, Schmidt GB. Mode of action of alanosine. Biochem Pharmacol. 1968 Mar;17(3):363-8. PubMed PMID: 5690813.

107: Marinone G, Robustelli della Cuna G, Marini G. [First experimental studies on the cytologic action in vivo of a new antibiotic with anticellular activity, the alanosine]. Haematologica. 1967;52(11):871-93. Italian. PubMed PMID: 4975736.

108: Murthy YK, Thiemann JE, Coronelli C, Sensi P. Alanosine, a new antiviral and antitumour agent isolated from a Streptomyces. Nature. 1966 Sep 10;211(5054):1198-9. PubMed PMID: 5970033.

109: Thiemann JE, Beretta G. Alanosine, a new antiviral and antitumor antibiotic from streptomyces. J Antibiot (Tokyo). 1966 Jul;19(4):155-60. PubMed PMID: 6013174.

110: Coronelli C, Pasqualucci CR, Tamoni G, Gallo GG. Isolation and structure of alanosine, a new antibiotic. Farmaco Sci. 1966 Apr;21(4):269-77. PubMed PMID: 5935557.